Genetic identification of familial hypercholesterolemia within a single U.S. Health care system

Science

Volumn 354, Issue 6319, 2016, Pages

  Abul Husn, Noura S ^a   Manickam, Kandamurugu ^b   Jones, Laney K ^b   Wright, Eric A ^b   Hartzel, Dustin N ^b   Gonzaga Jauregui, Claudia ^a   O'Dushlaine, Colm ^a   Leader, Joseph B ^b   Kirchner, H Lester ^b   Lindbuchler, D'Andra M ^b   Barr, Marci L ^b   Giovanni, Monica A ^b   Ritchie, Marylyn D ^b   Overton, John D ^a   Reid, Jeffrey G ^a   Metpally, Raghu P R ^b   Wardeh, Amr H ^b   Borecki, Ingrid B ^a   Yancopoulos, George D ^a   Baras, Aris ^a   Shuldiner, Alan R ^a   Gottesman, Omri ^a   Ledbetter, David H ^b   Carey, David J ^b   Dewey, Frederick E ^a   Murray, Michael F ^b   more..

^a AB)   (United States)

^b GEISINGER HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; COLORING AGENT; LOW DENSITY LIPOPROTEIN;

CARDIOVASCULAR DISEASE; CHEMICAL COMPOUND; DISEASE INCIDENCE; DISEASE PREVALENCE; GENETIC ANALYSIS; HEALTH CARE; HEALTH RISK; LIPID; PUBLIC HEALTH;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CLINICAL PRACTICE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; ELECTRONIC HEALTH RECORD; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENETIC IDENTIFICATION; GENETIC SCREENING; GENETIC VARIABILITY; GENOMICS; HEALTH CARE SYSTEM; HETEROZYGOTE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICATION THERAPY MANAGEMENT; MIDDLE AGED; ODDS RATIO; PREVALENCE; PRIORITY JOURNAL; UNITED STATES; WHOLE EXOME SEQUENCING; BLOOD; DRUG UTILIZATION; EXOME; GENETICS; HEALTH CARE DELIVERY; HYPERLIPOPROTEINEMIA TYPE II; STATISTICS AND NUMERICAL DATA;

UNITED STATES;

COLORING AGENTS; CORONARY ARTERY DISEASE; DELIVERY OF HEALTH CARE; DRUG UTILIZATION; ELECTRONIC HEALTH RECORDS; EXOME; GENETIC TESTING; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS, LDL; PREVALENCE; UNITED STATES;

EID: 85007138010     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.aaf7000     Document Type: Article

References (49)

1. M. S. Bowen, K. Kolor, W. D. Dotson, R. M. Ned, M. J. Khoury, Public health action in genomics is now needed beyond newborn screening. Public Health Genomics 15, 327-334 (2012). doi: 10.1159/000341889; pmid: 22986915
2. S. S. Gidding et al., The agenda for familial hypercholesterolemia: A scientific statement from the American Heart Association. Circulation 132, 2167-2192 (2015). doi: 10.1161/ CIR.0000000000000297; pmid: 26510694
3. A. C. Goldberg et al., Familial hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients: Clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J. Clin. Lipidol. 5, S1-S8 (2011). doi: 10.1016/j.jacl.2011.04.003; pmid: 21600525
4. B. G. Nordestgaard et al., Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease: Consensus statement of the European Atherosclerosis Society. Eur. Heart J. 34, 3478-3490 (2013). doi: 10.1093/eurheartj/ eht273; pmid: 23956253
5. J. L. Goldstein, H. G. Schrott, W. R. Hazzard, E. L. Bierman, A. G. Motulsky, Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J. Clin. Invest. 52, 1544-1568 (1973). doi: 10.1172/JCI107332; pmid: 4718953
6. P. N. Hopkins, P. P. Toth, C. M. Ballantyne, D. J. Rader, Familial hypercholesterolemias: Prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J. Clin. Lipidol. 5, S9-S17 (2011). doi: 10.1016/ j.jacl.2011.03.452; pmid: 21600530
7. D. Marks, M. Thorogood, H. A. Neil, S. E. Humphries, A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 168, 1-14 (2003). doi: 10.1016/S0021-9150(02)00330-1; pmid: 12732381
8. M. Benn, G. F. Watts, A. Tybjærg-Hansen, B. G. Nordestgaard, Mutations causative of familial hypercholesterolaemia: Screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. Eur. Heart J. 37, 1384-1394 (2016). doi: 10.1093/eurheartj/ehw028; pmid: 26908947
9. B. Sjouke et al., Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: Prevalence, genotype-phenotype relationship, and clinical outcome. Eur. Heart J. 36, 560-565 (2015). doi: 10.1093/eurheartj/ehu058; pmid: 24585268
10. M. A. Austin, C. M. Hutter, R. L. Zimmern, S. E. Humphries, Genetic causes of monogenic heterozygous familial hypercholesterolemia: A HuGE prevalence review. Am. J. Epidemiol. 160, 407-420 (2004). doi: 10.1093/aje/kwh236; pmid: 15321837
11. H. Shen et al., Familial defective apolipoprotein B-100 and increased low-density lipoprotein cholesterol and coronary artery calcification in the Old Order Amish. Arch. Intern. Med. 170, 1850-1855 (2010). doi: 10.1001/archinternmed.2010.384; pmid: 21059979
12. H. A. Neil, T. Hammond, R. Huxley, D. R. Matthews, S. E. Humphries, Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: Prospective registry study. BMJ 321, 148 (2000). doi: 10.1136/bmj.321.7254.148; pmid: 10894692
13. A. H. Pijlman et al., Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: A large cross-sectional study in The Netherlands. Atherosclerosis 209, 189-194 (2010). doi: 10.1016/ j.atherosclerosis.2009.09.014; pmid: 19818960
14. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 303, 893-896 (1991). doi: 10.1136/bmj.303.6807.893; pmid: 1933004
15. F. Civeira; International Panel on Management of Familial Hypercholesterolemia, Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 173, 55-68 (2004). doi: 10.1016/ j.atherosclerosis.2003.11.010; pmid: 15177124
16. World Health Organization, Familial Hypercholesterolemia: Report of a Second WHO Consultation (World Health Organization, 1998).
17. R. R. Williams et al., Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am. J. Cardiol. 72, 171-176 (1993). doi: 10.1016/0002-9149(93)90155-6; pmid: 8328379
18. D. J. Carey et al., The Geisinger MyCode community health initiative: An electronic health record-linked biobank for precision medicine research. Genet. Med. 18, 906-913 (2016). doi: 10.1038/gim.2015.187; pmid: 26866580
19. F. E. Dewey et al., Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study, Science 354, aaf6814 (2016).
20. N. J. Stone et al., 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 63, 2889-2934 (2014). doi: 10.1016/j.jacc.2013.11.002; pmid: 24239923
21. J. S. Packer et al., CLAMMS: A scalable algorithm for calling common and rare copy number variants from exome sequencing data. Bioinformatics 32, 133-135 (2016). doi: 10.1093/ bioinformatics/btv547; pmid: 26382196
22. M. J. Landrum et al., ClinVar: Public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 42, D980-D985 (2014). doi: 10.1093/nar/gkt1113; pmid: 24234437
23. A. V. Khera et al., Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J. Am. Coll. Cardiol. 67, 2578-2589 (2016). doi: 10.1016/j.jacc.2016.03.520; pmid: 27050191
24. J. Staples, D. Qiao, M. H. Cho, E. K. Silverman, D. A. Nickerson, PRIMUS: Rapid reconstruction of pedigrees from genome-wide estimates of identity by descent. Am. J. Hum. Genet. 95, 553-564 (2014). doi: 10.1016/j.ajhg.2014.10.005; pmid: 25439724
25. F. E. Dewey et al., Inactivating variants in ANGPTL4 and risk of coronary artery disease. N. Engl. J. Med. 374, 1123-1133 (2016). doi: 10.1056/NEJMoa1510926; pmid: 26933753
26. J. G. Robinson, A. C. Goldberg, Treatment of adults with familial hypercholesterolemia and evidence for treatment: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J. Clin. Lipidol. 5, S18-S29 (2011). doi: 10.1016/j.jacl.2011.03.451; pmid: 21600526
27. T. A. Jacobson et al., National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 2. J. Clin. Lipidol. 9, S1-S122.e1 (2015). doi: 10.1016/j.jacl.2015.09.002; pmid: 26699442
28. H. Tada et al., Multiple associated variants increase the heritability explained for plasma lipids and coronary artery disease. Circ. Cardiovasc. Genet. 7, 583-587 (2014). doi: 10.1161/CIRCGENETICS.113.000420; pmid: 25170055
29. T. M. Teslovich et al., Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466, 707-713 (2010). doi: 10.1038/nature09270; pmid: 20686565
30. D. Vodnala, M. Rubenfire, R. D. Brook, Secondary causes of dyslipidemia. Am. J. Cardiol. 110, 823-825 (2012). doi: 10.1016/j.amjcard.2012.04.062; pmid: 22658245
31. L. Troeung et al., A new electronic screening tool for identifying risk of familial hypercholesterolaemia in general practice. Heart 102, 855-861 (2016). doi: 10.1136/ heartjnl-2015-308824; pmid: 26864669
32. The FH Foundation, FIND FH Initiative, https:// thefhfoundation.org/find-fh/ [accessed 21 June 2016].
33. Ž. Reiner et al., ESC/EAS guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 32, 1769-1818 (2011). doi: 10.1016/ j.atherosclerosis.2011.06.028; pmid: 21712404
34. M. Benn, G. F. Watts, A. Tybjaerg-Hansen, B. G. Nordestgaard, Familial hypercholesterolemia in the Danish general population: Prevalence, coronary artery disease, and cholesterol-lowering medication. J. Clin. Endocrinol. Metab. 97, 3956-3964 (2012). doi: 10.1210/jc.2012-1563; pmid: 22893714
35. F. J. Raal et al., Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 124, 2202-2207 (2011). doi: 10.1161/CIRCULATIONAHA.111.042523; pmid: 21986285
36. A. Andermann, I. Blancquaert, S. Beauchamp, V. Déry, Revisiting Wilson and Jungner in the genomic age: A review of screening criteria over the past 40 years. Bull. World Health Organ. 86, 317-319 (2008). doi: 10.2471/BLT.00.000000; pmid: 18438522
37. L. G. Biesecker, R. C. Green, Diagnostic clinical genome and exome sequencing. N. Engl. J. Med. 370, 2418-2425 (2014). doi: 10.1056/NEJMra1312543; pmid: 24941179
38. D. Wonderling et al., Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands. Semin. Vasc. Med. 4, 97-104 (2004). doi: 10.1055/s-2004-822992; pmid: 15199439
39. C. X. Chen, J. W. Hay, Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States. Int. J. Cardiol. 181, 417-424 (2015). doi: 10.1016/ j.ijcard.2014.12.070; pmid: 25569270
40. E. A. Ashley, The precision medicine initiative: A new national effort. JAMA 313, 2119-2120 (2015). doi: 10.1001/ jama.2015.3595; pmid: 25928209
41. M. J. Khoury, J. P. Evans, A public health perspective on a national precision medicine cohort: Balancing long-term knowledge generation with early health benefit. JAMA 313, 2117-2118 (2015). doi: 10.1001/jama.2015.3382; pmid: 26034952
42. R. C. Green et al., ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet. Med. 15, 565-574 (2013). doi: 10.1038/gim.2013.73; pmid: 23788249
43. J. G. Reid et al., Launching genomics into the cloud: Deployment of Mercury, a next generation sequence analysis pipeline. BMC Bioinformatics 15, 30 (2014). doi: 10.1186/ 1471-2105-15-30; pmid: 24475911
44. H. Li, R. Durbin, Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009). doi: 10.1093/bioinformatics/btp324; pmid: 19451168
45. A. McKenna et al., The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297-1303 (2010). doi: 10.1101/ gr.107524.110; pmid: 20644199
46. G. A. Van der Auwera et al., From FastQ data to high confidence variant calls: The Genome Analysis Toolkit best practices pipeline. Curr. Protoc. Bioinformatics 43, 11.10.1-11.10.33 (2013). doi: 10.1002/0471250953.bi1110s43; pmid: 25431634
47. P. Cingolani et al., A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly 6, 80-92 (2012). doi: 10.4161/fly.19695; pmid: 22728672
48. G. Heinze, M. Schemper, A solution to the problem of separation in logistic regression. Stat. Med. 21, 2409-2419 (2002). doi: 10.1002/(ISSN)1097-0258; pmid: 12210625
49. J. Yang, S. H. Lee, M. E. Goddard, P. M. Visscher, GCTA: A tool for genome-wide complex trait analysis. Am. J. Hum. Genet. 88, 76-82 (2011). doi: 10.1016/j.ajhg.2010.11.011; pmid: 12210625